CTLA4 and neoplasm: Together, these findings suggest the therapeutic action of anti-CTLA-4 to rest mainly on pre-existing anti-tumor reactivity and to occur despite the on-treatment remodeling of the peripheral TCR repertoire rather than as a result of it.